nodes	percent_of_prediction	percent_of_DWPC	metapath
Disopyramide—SLC22A2—Cytarabine—lymphatic system cancer	0.326	0.422	CbGbCtD
Disopyramide—SLC22A1—Cytarabine—lymphatic system cancer	0.283	0.366	CbGbCtD
Disopyramide—CYP3A4—Cytarabine—lymphatic system cancer	0.052	0.0673	CbGbCtD
Disopyramide—CYP3A4—Teniposide—lymphatic system cancer	0.0512	0.0663	CbGbCtD
Disopyramide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0358	0.0463	CbGbCtD
Disopyramide—CYP3A4—Vincristine—lymphatic system cancer	0.0246	0.0319	CbGbCtD
Disopyramide—Coma—Fludarabine—lymphatic system cancer	0.00264	0.0116	CcSEcCtD
Disopyramide—Haemoglobin decreased—Mitoxantrone—lymphatic system cancer	0.0025	0.011	CcSEcCtD
Disopyramide—Depression—Mechlorethamine—lymphatic system cancer	0.00248	0.0109	CcSEcCtD
Disopyramide—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00233	0.0102	CcSEcCtD
Disopyramide—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.00231	0.0102	CcSEcCtD
Disopyramide—Cardiac failure—Fludarabine—lymphatic system cancer	0.00215	0.00944	CcSEcCtD
Disopyramide—Numbness—Vincristine—lymphatic system cancer	0.00213	0.00935	CcSEcCtD
Disopyramide—Sensory loss—Vincristine—lymphatic system cancer	0.00204	0.00895	CcSEcCtD
Disopyramide—Neutropenia—Teniposide—lymphatic system cancer	0.00193	0.00847	CcSEcCtD
Disopyramide—Hepatic enzyme increased—Mitoxantrone—lymphatic system cancer	0.00182	0.00798	CcSEcCtD
Disopyramide—Sweating increased—Fludarabine—lymphatic system cancer	0.00176	0.00776	CcSEcCtD
Disopyramide—Vertigo—Mechlorethamine—lymphatic system cancer	0.00175	0.00769	CcSEcCtD
Disopyramide—Dysuria—Fludarabine—lymphatic system cancer	0.00169	0.00744	CcSEcCtD
Disopyramide—Neutropenia—Fludarabine—lymphatic system cancer	0.00169	0.00744	CcSEcCtD
Disopyramide—Coma—Carmustine—lymphatic system cancer	0.00169	0.00742	CcSEcCtD
Disopyramide—Gynaecomastia—Carmustine—lymphatic system cancer	0.00165	0.00727	CcSEcCtD
Disopyramide—Blood urea increased—Mitoxantrone—lymphatic system cancer	0.00162	0.00713	CcSEcCtD
Disopyramide—Coma—Vincristine—lymphatic system cancer	0.00161	0.00708	CcSEcCtD
Disopyramide—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00156	0.00684	CcSEcCtD
Disopyramide—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00154	0.00679	CcSEcCtD
Disopyramide—Anorexia—Mechlorethamine—lymphatic system cancer	0.00152	0.00666	CcSEcCtD
Disopyramide—Arrhythmia—Teniposide—lymphatic system cancer	0.00147	0.00648	CcSEcCtD
Disopyramide—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00144	0.00634	CcSEcCtD
Disopyramide—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00138	0.00607	CcSEcCtD
Disopyramide—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00137	0.00604	CcSEcCtD
Disopyramide—Diplopia—Carmustine—lymphatic system cancer	0.00134	0.0059	CcSEcCtD
Disopyramide—Arrhythmia—Fludarabine—lymphatic system cancer	0.00129	0.00569	CcSEcCtD
Disopyramide—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00128	0.00562	CcSEcCtD
Disopyramide—Chest pain—Teniposide—lymphatic system cancer	0.00122	0.00537	CcSEcCtD
Disopyramide—Hypokalaemia—Carmustine—lymphatic system cancer	0.00122	0.00537	CcSEcCtD
Disopyramide—Cardiac arrest—Vincristine—lymphatic system cancer	0.00122	0.00535	CcSEcCtD
Disopyramide—Urinary retention—Vincristine—lymphatic system cancer	0.00122	0.00535	CcSEcCtD
Disopyramide—Cyanosis—Methotrexate—lymphatic system cancer	0.00121	0.00531	CcSEcCtD
Disopyramide—Muscular weakness—Carmustine—lymphatic system cancer	0.00118	0.0052	CcSEcCtD
Disopyramide—Confusional state—Teniposide—lymphatic system cancer	0.00118	0.00519	CcSEcCtD
Disopyramide—Oedema—Teniposide—lymphatic system cancer	0.00117	0.00515	CcSEcCtD
Disopyramide—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00117	0.00515	CcSEcCtD
Disopyramide—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00117	0.00513	CcSEcCtD
Disopyramide—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00115	0.00504	CcSEcCtD
Disopyramide—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00114	0.00501	CcSEcCtD
Disopyramide—Malaise—Fludarabine—lymphatic system cancer	0.00114	0.005	CcSEcCtD
Disopyramide—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00113	0.00499	CcSEcCtD
Disopyramide—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00113	0.00498	CcSEcCtD
Disopyramide—Muscular weakness—Vincristine—lymphatic system cancer	0.00113	0.00496	CcSEcCtD
Disopyramide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00112	0.00494	CcSEcCtD
Disopyramide—Anorexia—Teniposide—lymphatic system cancer	0.00112	0.00491	CcSEcCtD
Disopyramide—Hypotension—Teniposide—lymphatic system cancer	0.00109	0.00481	CcSEcCtD
Disopyramide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00109	0.00478	CcSEcCtD
Disopyramide—Neutropenia—Carmustine—lymphatic system cancer	0.00108	0.00476	CcSEcCtD
Disopyramide—Discomfort—Fludarabine—lymphatic system cancer	0.00106	0.00467	CcSEcCtD
Disopyramide—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00106	0.00465	CcSEcCtD
Disopyramide—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00105	0.00461	CcSEcCtD
Disopyramide—Dyspnoea—Teniposide—lymphatic system cancer	0.00104	0.00459	CcSEcCtD
Disopyramide—Confusional state—Fludarabine—lymphatic system cancer	0.00104	0.00456	CcSEcCtD
Disopyramide—Neutropenia—Vincristine—lymphatic system cancer	0.00103	0.00455	CcSEcCtD
Disopyramide—Dysuria—Vincristine—lymphatic system cancer	0.00103	0.00455	CcSEcCtD
Disopyramide—Depression—Carmustine—lymphatic system cancer	0.00103	0.00453	CcSEcCtD
Disopyramide—Oedema—Fludarabine—lymphatic system cancer	0.00103	0.00453	CcSEcCtD
Disopyramide—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00102	0.00448	CcSEcCtD
Disopyramide—Decreased appetite—Teniposide—lymphatic system cancer	0.00102	0.00448	CcSEcCtD
Disopyramide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00101	0.00444	CcSEcCtD
Disopyramide—Apnoea—Methotrexate—lymphatic system cancer	0.00101	0.00444	CcSEcCtD
Disopyramide—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00101	0.00443	CcSEcCtD
Disopyramide—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00101	0.00443	CcSEcCtD
Disopyramide—Rash—Mechlorethamine—lymphatic system cancer	0.001	0.00441	CcSEcCtD
Disopyramide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.001	0.0044	CcSEcCtD
Disopyramide—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000996	0.00438	CcSEcCtD
Disopyramide—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.000992	0.00436	CcSEcCtD
Disopyramide—Depression—Vincristine—lymphatic system cancer	0.000984	0.00432	CcSEcCtD
Disopyramide—Anorexia—Fludarabine—lymphatic system cancer	0.000982	0.00432	CcSEcCtD
Disopyramide—Weight increased—Mitoxantrone—lymphatic system cancer	0.000981	0.00431	CcSEcCtD
Disopyramide—Feeling abnormal—Teniposide—lymphatic system cancer	0.000966	0.00424	CcSEcCtD
Disopyramide—Drowsiness—Mitoxantrone—lymphatic system cancer	0.000961	0.00422	CcSEcCtD
Disopyramide—Nausea—Mechlorethamine—lymphatic system cancer	0.000944	0.00415	CcSEcCtD
Disopyramide—Urticaria—Teniposide—lymphatic system cancer	0.000931	0.00409	CcSEcCtD
Disopyramide—Body temperature increased—Teniposide—lymphatic system cancer	0.000926	0.00407	CcSEcCtD
Disopyramide—Paraesthesia—Fludarabine—lymphatic system cancer	0.000925	0.00407	CcSEcCtD
Disopyramide—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000923	0.00406	CcSEcCtD
Disopyramide—Dyspnoea—Fludarabine—lymphatic system cancer	0.000918	0.00404	CcSEcCtD
Disopyramide—Dyspepsia—Fludarabine—lymphatic system cancer	0.000907	0.00399	CcSEcCtD
Disopyramide—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.000905	0.00398	CcSEcCtD
Disopyramide—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000897	0.00394	CcSEcCtD
Disopyramide—Decreased appetite—Fludarabine—lymphatic system cancer	0.000895	0.00394	CcSEcCtD
Disopyramide—Fatigue—Fludarabine—lymphatic system cancer	0.000888	0.0039	CcSEcCtD
Disopyramide—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000881	0.00387	CcSEcCtD
Disopyramide—Pain—Fludarabine—lymphatic system cancer	0.000881	0.00387	CcSEcCtD
Disopyramide—Constipation—Fludarabine—lymphatic system cancer	0.000881	0.00387	CcSEcCtD
Disopyramide—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000878	0.00386	CcSEcCtD
Disopyramide—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000862	0.00379	CcSEcCtD
Disopyramide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000858	0.00377	CcSEcCtD
Disopyramide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000849	0.00373	CcSEcCtD
Disopyramide—Asthenia—Teniposide—lymphatic system cancer	0.000841	0.0037	CcSEcCtD
Disopyramide—Malaise—Bleomycin—lymphatic system cancer	0.000834	0.00367	CcSEcCtD
Disopyramide—Pruritus—Teniposide—lymphatic system cancer	0.000829	0.00364	CcSEcCtD
Disopyramide—Arrhythmia—Carmustine—lymphatic system cancer	0.000829	0.00364	CcSEcCtD
Disopyramide—Body temperature increased—Fludarabine—lymphatic system cancer	0.000814	0.00358	CcSEcCtD
Disopyramide—Diarrhoea—Teniposide—lymphatic system cancer	0.000802	0.00352	CcSEcCtD
Disopyramide—Chest pain—Bleomycin—lymphatic system cancer	0.000788	0.00346	CcSEcCtD
Disopyramide—Coma—Methotrexate—lymphatic system cancer	0.000782	0.00344	CcSEcCtD
Disopyramide—Discomfort—Bleomycin—lymphatic system cancer	0.000778	0.00342	CcSEcCtD
Disopyramide—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00077	0.00339	CcSEcCtD
Disopyramide—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000766	0.00337	CcSEcCtD
Disopyramide—Confusional state—Bleomycin—lymphatic system cancer	0.000761	0.00335	CcSEcCtD
Disopyramide—Vision blurred—Carmustine—lymphatic system cancer	0.000761	0.00335	CcSEcCtD
Disopyramide—Oedema—Bleomycin—lymphatic system cancer	0.000755	0.00332	CcSEcCtD
Disopyramide—Vomiting—Teniposide—lymphatic system cancer	0.000745	0.00328	CcSEcCtD
Disopyramide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000739	0.00325	CcSEcCtD
Disopyramide—Asthenia—Fludarabine—lymphatic system cancer	0.000739	0.00325	CcSEcCtD
Disopyramide—Rash—Teniposide—lymphatic system cancer	0.000739	0.00325	CcSEcCtD
Disopyramide—Dermatitis—Teniposide—lymphatic system cancer	0.000738	0.00324	CcSEcCtD
Disopyramide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000735	0.00323	CcSEcCtD
Disopyramide—Headache—Teniposide—lymphatic system cancer	0.000734	0.00323	CcSEcCtD
Disopyramide—Pruritus—Fludarabine—lymphatic system cancer	0.000729	0.0032	CcSEcCtD
Disopyramide—Anorexia—Bleomycin—lymphatic system cancer	0.00072	0.00316	CcSEcCtD
Disopyramide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000708	0.00311	CcSEcCtD
Disopyramide—Hypotension—Bleomycin—lymphatic system cancer	0.000706	0.0031	CcSEcCtD
Disopyramide—Diarrhoea—Fludarabine—lymphatic system cancer	0.000705	0.0031	CcSEcCtD
Disopyramide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000697	0.00306	CcSEcCtD
Disopyramide—Nausea—Teniposide—lymphatic system cancer	0.000696	0.00306	CcSEcCtD
Disopyramide—Vertigo—Vincristine—lymphatic system cancer	0.000693	0.00304	CcSEcCtD
Disopyramide—Chest pain—Carmustine—lymphatic system cancer	0.000688	0.00302	CcSEcCtD
Disopyramide—Paraesthesia—Bleomycin—lymphatic system cancer	0.000678	0.00298	CcSEcCtD
Disopyramide—Malaise—Mitoxantrone—lymphatic system cancer	0.000677	0.00298	CcSEcCtD
Disopyramide—Dyspnoea—Bleomycin—lymphatic system cancer	0.000673	0.00296	CcSEcCtD
Disopyramide—Confusional state—Carmustine—lymphatic system cancer	0.000665	0.00292	CcSEcCtD
Disopyramide—Oedema—Carmustine—lymphatic system cancer	0.000659	0.0029	CcSEcCtD
Disopyramide—Decreased appetite—Bleomycin—lymphatic system cancer	0.000656	0.00289	CcSEcCtD
Disopyramide—Vomiting—Fludarabine—lymphatic system cancer	0.000655	0.00288	CcSEcCtD
Disopyramide—Rash—Fludarabine—lymphatic system cancer	0.000649	0.00285	CcSEcCtD
Disopyramide—Dermatitis—Fludarabine—lymphatic system cancer	0.000649	0.00285	CcSEcCtD
Disopyramide—Pain—Bleomycin—lymphatic system cancer	0.000646	0.00284	CcSEcCtD
Disopyramide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000645	0.00284	CcSEcCtD
Disopyramide—Headache—Fludarabine—lymphatic system cancer	0.000645	0.00284	CcSEcCtD
Disopyramide—Chest pain—Mitoxantrone—lymphatic system cancer	0.000639	0.00281	CcSEcCtD
Disopyramide—Discomfort—Mitoxantrone—lymphatic system cancer	0.000632	0.00278	CcSEcCtD
Disopyramide—Oedema—Vincristine—lymphatic system cancer	0.000629	0.00277	CcSEcCtD
Disopyramide—Anorexia—Carmustine—lymphatic system cancer	0.000628	0.00276	CcSEcCtD
Disopyramide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000622	0.00274	CcSEcCtD
Disopyramide—Confusional state—Mitoxantrone—lymphatic system cancer	0.000618	0.00272	CcSEcCtD
Disopyramide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000616	0.00271	CcSEcCtD
Disopyramide—Hypotension—Carmustine—lymphatic system cancer	0.000616	0.00271	CcSEcCtD
Disopyramide—Oedema—Mitoxantrone—lymphatic system cancer	0.000613	0.00269	CcSEcCtD
Disopyramide—Nausea—Fludarabine—lymphatic system cancer	0.000612	0.00269	CcSEcCtD
Disopyramide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000608	0.00267	CcSEcCtD
Disopyramide—Shock—Mitoxantrone—lymphatic system cancer	0.000603	0.00265	CcSEcCtD
Disopyramide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.0006	0.00264	CcSEcCtD
Disopyramide—Urticaria—Bleomycin—lymphatic system cancer	0.0006	0.00264	CcSEcCtD
Disopyramide—Anorexia—Vincristine—lymphatic system cancer	0.0006	0.00264	CcSEcCtD
Disopyramide—Body temperature increased—Bleomycin—lymphatic system cancer	0.000597	0.00262	CcSEcCtD
Disopyramide—Insomnia—Carmustine—lymphatic system cancer	0.000596	0.00262	CcSEcCtD
Disopyramide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000595	0.00262	CcSEcCtD
Disopyramide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000592	0.0026	CcSEcCtD
Disopyramide—Paraesthesia—Carmustine—lymphatic system cancer	0.000592	0.0026	CcSEcCtD
Disopyramide—Hypotension—Vincristine—lymphatic system cancer	0.000588	0.00258	CcSEcCtD
Disopyramide—Dyspnoea—Carmustine—lymphatic system cancer	0.000588	0.00258	CcSEcCtD
Disopyramide—Somnolence—Carmustine—lymphatic system cancer	0.000586	0.00258	CcSEcCtD
Disopyramide—Anorexia—Mitoxantrone—lymphatic system cancer	0.000584	0.00257	CcSEcCtD
Disopyramide—Decreased appetite—Carmustine—lymphatic system cancer	0.000573	0.00252	CcSEcCtD
Disopyramide—Hypotension—Mitoxantrone—lymphatic system cancer	0.000573	0.00252	CcSEcCtD
Disopyramide—Insomnia—Vincristine—lymphatic system cancer	0.000569	0.0025	CcSEcCtD
Disopyramide—Paraesthesia—Vincristine—lymphatic system cancer	0.000565	0.00248	CcSEcCtD
Disopyramide—Pain—Carmustine—lymphatic system cancer	0.000564	0.00248	CcSEcCtD
Disopyramide—Constipation—Carmustine—lymphatic system cancer	0.000564	0.00248	CcSEcCtD
Disopyramide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00055	0.00242	CcSEcCtD
Disopyramide—Decreased appetite—Vincristine—lymphatic system cancer	0.000547	0.0024	CcSEcCtD
Disopyramide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000546	0.0024	CcSEcCtD
Disopyramide—Somnolence—Mitoxantrone—lymphatic system cancer	0.000545	0.00239	CcSEcCtD
Disopyramide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000543	0.00239	CcSEcCtD
Disopyramide—Fatigue—Vincristine—lymphatic system cancer	0.000542	0.00238	CcSEcCtD
Disopyramide—Asthenia—Bleomycin—lymphatic system cancer	0.000542	0.00238	CcSEcCtD
Disopyramide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000539	0.00237	CcSEcCtD
Disopyramide—Pain—Vincristine—lymphatic system cancer	0.000538	0.00237	CcSEcCtD
Disopyramide—Constipation—Vincristine—lymphatic system cancer	0.000538	0.00237	CcSEcCtD
Disopyramide—Pruritus—Bleomycin—lymphatic system cancer	0.000534	0.00235	CcSEcCtD
Disopyramide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000533	0.00234	CcSEcCtD
Disopyramide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000528	0.00232	CcSEcCtD
Disopyramide—Pain—Mitoxantrone—lymphatic system cancer	0.000524	0.0023	CcSEcCtD
Disopyramide—Constipation—Mitoxantrone—lymphatic system cancer	0.000524	0.0023	CcSEcCtD
Disopyramide—Body temperature increased—Carmustine—lymphatic system cancer	0.000521	0.00229	CcSEcCtD
Disopyramide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000505	0.00222	CcSEcCtD
Disopyramide—Dysuria—Methotrexate—lymphatic system cancer	0.000502	0.00221	CcSEcCtD
Disopyramide—Neutropenia—Methotrexate—lymphatic system cancer	0.000502	0.00221	CcSEcCtD
Disopyramide—Body temperature increased—Vincristine—lymphatic system cancer	0.000497	0.00219	CcSEcCtD
Disopyramide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000494	0.00217	CcSEcCtD
Disopyramide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000487	0.00214	CcSEcCtD
Disopyramide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000484	0.00213	CcSEcCtD
Disopyramide—Vomiting—Bleomycin—lymphatic system cancer	0.00048	0.00211	CcSEcCtD
Disopyramide—Drowsiness—Methotrexate—lymphatic system cancer	0.000479	0.0021	CcSEcCtD
Disopyramide—Depression—Methotrexate—lymphatic system cancer	0.000477	0.0021	CcSEcCtD
Disopyramide—Rash—Bleomycin—lymphatic system cancer	0.000476	0.00209	CcSEcCtD
Disopyramide—Dermatitis—Bleomycin—lymphatic system cancer	0.000476	0.00209	CcSEcCtD
Disopyramide—Asthenia—Carmustine—lymphatic system cancer	0.000473	0.00208	CcSEcCtD
Disopyramide—Asthenia—Vincristine—lymphatic system cancer	0.000451	0.00198	CcSEcCtD
Disopyramide—Diarrhoea—Carmustine—lymphatic system cancer	0.000451	0.00198	CcSEcCtD
Disopyramide—Nausea—Bleomycin—lymphatic system cancer	0.000449	0.00197	CcSEcCtD
Disopyramide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000447	0.00196	CcSEcCtD
Disopyramide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00044	0.00193	CcSEcCtD
Disopyramide—Dizziness—Carmustine—lymphatic system cancer	0.000436	0.00192	CcSEcCtD
Disopyramide—Diarrhoea—Vincristine—lymphatic system cancer	0.00043	0.00189	CcSEcCtD
Disopyramide—Hepatitis—Methotrexate—lymphatic system cancer	0.00043	0.00189	CcSEcCtD
Disopyramide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000419	0.00184	CcSEcCtD
Disopyramide—Vomiting—Carmustine—lymphatic system cancer	0.000419	0.00184	CcSEcCtD
Disopyramide—Dizziness—Vincristine—lymphatic system cancer	0.000416	0.00183	CcSEcCtD
Disopyramide—Rash—Carmustine—lymphatic system cancer	0.000416	0.00183	CcSEcCtD
Disopyramide—Dermatitis—Carmustine—lymphatic system cancer	0.000415	0.00183	CcSEcCtD
Disopyramide—Headache—Carmustine—lymphatic system cancer	0.000413	0.00182	CcSEcCtD
Disopyramide—Vomiting—Vincristine—lymphatic system cancer	0.0004	0.00176	CcSEcCtD
Disopyramide—Rash—Vincristine—lymphatic system cancer	0.000397	0.00174	CcSEcCtD
Disopyramide—Dermatitis—Vincristine—lymphatic system cancer	0.000396	0.00174	CcSEcCtD
Disopyramide—Headache—Vincristine—lymphatic system cancer	0.000394	0.00173	CcSEcCtD
Disopyramide—Nausea—Carmustine—lymphatic system cancer	0.000391	0.00172	CcSEcCtD
Disopyramide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00039	0.00171	CcSEcCtD
Disopyramide—Rash—Mitoxantrone—lymphatic system cancer	0.000386	0.0017	CcSEcCtD
Disopyramide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000386	0.0017	CcSEcCtD
Disopyramide—Headache—Mitoxantrone—lymphatic system cancer	0.000384	0.00169	CcSEcCtD
Disopyramide—Nausea—Vincristine—lymphatic system cancer	0.000374	0.00164	CcSEcCtD
Disopyramide—Dysgeusia—Methotrexate—lymphatic system cancer	0.000366	0.00161	CcSEcCtD
Disopyramide—Nausea—Mitoxantrone—lymphatic system cancer	0.000364	0.0016	CcSEcCtD
Disopyramide—Vision blurred—Methotrexate—lymphatic system cancer	0.000353	0.00155	CcSEcCtD
Disopyramide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000347	0.00153	CcSEcCtD
Disopyramide—Malaise—Methotrexate—lymphatic system cancer	0.000337	0.00148	CcSEcCtD
Disopyramide—Vertigo—Methotrexate—lymphatic system cancer	0.000336	0.00148	CcSEcCtD
Disopyramide—Chest pain—Methotrexate—lymphatic system cancer	0.000318	0.0014	CcSEcCtD
Disopyramide—Discomfort—Methotrexate—lymphatic system cancer	0.000315	0.00138	CcSEcCtD
Disopyramide—Confusional state—Methotrexate—lymphatic system cancer	0.000308	0.00135	CcSEcCtD
Disopyramide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000299	0.00131	CcSEcCtD
Disopyramide—Skin disorder—Methotrexate—lymphatic system cancer	0.000297	0.0013	CcSEcCtD
Disopyramide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000295	0.0013	CcSEcCtD
Disopyramide—Anorexia—Methotrexate—lymphatic system cancer	0.000291	0.00128	CcSEcCtD
Disopyramide—Hypotension—Methotrexate—lymphatic system cancer	0.000285	0.00125	CcSEcCtD
Disopyramide—Insomnia—Methotrexate—lymphatic system cancer	0.000276	0.00121	CcSEcCtD
Disopyramide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000274	0.00121	CcSEcCtD
Disopyramide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000272	0.0012	CcSEcCtD
Disopyramide—Somnolence—Methotrexate—lymphatic system cancer	0.000271	0.00119	CcSEcCtD
Disopyramide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000269	0.00118	CcSEcCtD
Disopyramide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000265	0.00117	CcSEcCtD
Disopyramide—Fatigue—Methotrexate—lymphatic system cancer	0.000263	0.00116	CcSEcCtD
Disopyramide—Pain—Methotrexate—lymphatic system cancer	0.000261	0.00115	CcSEcCtD
Disopyramide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000252	0.00111	CcSEcCtD
Disopyramide—Urticaria—Methotrexate—lymphatic system cancer	0.000243	0.00107	CcSEcCtD
Disopyramide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000241	0.00106	CcSEcCtD
Disopyramide—Asthenia—Methotrexate—lymphatic system cancer	0.000219	0.000963	CcSEcCtD
Disopyramide—Pruritus—Methotrexate—lymphatic system cancer	0.000216	0.00095	CcSEcCtD
Disopyramide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000209	0.000918	CcSEcCtD
Disopyramide—Dizziness—Methotrexate—lymphatic system cancer	0.000202	0.000888	CcSEcCtD
Disopyramide—Vomiting—Methotrexate—lymphatic system cancer	0.000194	0.000853	CcSEcCtD
Disopyramide—Rash—Methotrexate—lymphatic system cancer	0.000192	0.000846	CcSEcCtD
Disopyramide—Dermatitis—Methotrexate—lymphatic system cancer	0.000192	0.000845	CcSEcCtD
Disopyramide—Headache—Methotrexate—lymphatic system cancer	0.000191	0.000841	CcSEcCtD
Disopyramide—Nausea—Methotrexate—lymphatic system cancer	0.000181	0.000797	CcSEcCtD
